The following is a summary of “Cardiovascular events in patients with gout initiating urate-lowering therapy with or without ...

Time to crystal clearance relates to disease duration and to the serum uric acid level achieved with therapy. The current recommended target level by most guidelines is 360 µmol/l (6 mg/dl), but ...

A new study finds that obesity significantly reduces the effectiveness of urate-lowering therapy in male gout patients, with ...

Obesity significantly reduced the effectiveness of febuxostat-based urate-lowering therapy among men with gout, with those with obesity showing lower target achievement rates and more flares than ...